<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514146</url>
  </required_header>
  <id_info>
    <org_study_id>TNHF2020-2VAT</org_study_id>
    <nct_id>NCT04514146</nct_id>
  </id_info>
  <brief_title>The Effects of Water-only Fasting and Refeeding on Body Composition</brief_title>
  <official_title>A Pilot Study on the Effects of Water-only Fasting and Refeeding on Body Composition and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TrueNorth Health Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TrueNorth Health Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational pilot study will assess the effects of water-only fasting on body&#xD;
      composition and insulin resistance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will explore the effects of water-only fasting followed by an exclusively&#xD;
      whole-plant-food diet free of added salt, oil, and sugar on body composition with a&#xD;
      particular focus on visceral adipose tissue (VAT). The study will also extend a previous&#xD;
      study assessing the effects of fasting and refeeding on Homeostatic Model Assessment of&#xD;
      Insulin Resistance (HOMA-IR) values and markers of cardiovascular health and inflammation by&#xD;
      following participants for an additional 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean changes in visceral adipose tissue from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>Visceral adipose tissue will be estimated using Holigic Horizon dual-energy X-ray absorptiometry (DXA) machine and reported in grams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean changes in total fat and lean mass and bone mineral content (BMC) from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>Total fat and lean mass and BMC will be estimated using Holigic Horizon dual-energy X-ray absorptiometry (DXA) machine and reported in grams</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean changes in lipid profile from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>Lipid profile will be assessed using serum to measure cholesterol, triglycerides, high-density lipoprotein (HDL), and lowdensity lipoprotein (LDL) and reported in mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean changes in weight from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>Weight will be measured on a digital scale and reported in kilograms (kg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean changes in insulin resistance from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>Insulin resistance will be assessed using serum glucose and insulin to calculate homeostatic model of insulin resistance (HOMA-IR) [fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5]</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean changes in abdominal circumference from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>Abdominal circumference will be measured on bare skin at the minimal waistline with a tension-sensitive, non-elastic tape and reported in centimeters (cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean changes in high sensitivity C-reactive protein (hs-CRP) from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>hsCRP will assessed using serum and reported in mg/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean changes in Gamma-Glutamyl-Transferase (GGT) from baseline</measure>
    <time_frame>Baseline, up to 10 to 40 days after baseline, up to 5 to 20 days after end of fast, 6-weeks after end of refeed</time_frame>
    <description>GGT will assessed using serum and reported in U/L</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Visceral Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Water-only Fasting Group</arm_group_label>
    <description>Overweight and obese, non-diabetic participants undergoing elective water-only fasting treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water-only fasting</intervention_name>
    <description>In-patient water-only fasting for at least 10 days followed by at least 5 days of refeeding</description>
    <arm_group_label>Water-only Fasting Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sera and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Overweight and obese, non-diabetic participants chosen from voluntary patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any gender&#xD;
&#xD;
          -  40-70 years old&#xD;
&#xD;
          -  Fasting plasma glucose &lt;126mg/dL and/or hemoglobin A1c &lt;7%&#xD;
&#xD;
          -  BMI between 25 and 40 kg/m2&#xD;
&#xD;
          -  Elect and qualify for a water-only fast of at least 10 consecutive days&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Internet and computer access&#xD;
&#xD;
          -  Able to return for 6-week follow-up visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Active inflammatory disorder including classic autoimmune connective tissue (Lupus,&#xD;
             Sjogrens, ANCA), multiple sclerosis, and inflammatory bowel disorders (Ulcerative&#xD;
             colitis, Crohn's)&#xD;
&#xD;
          -  Stroke or heart attack within the last 12 months&#xD;
&#xD;
          -  Break water-only fast before 10 days with juice or food.&#xD;
&#xD;
          -  Break water-only fast after 10 days with juice or food before end-of-fast blood draw&#xD;
             occurs.&#xD;
&#xD;
          -  Leave center before completing at least 5 days of refeeding&#xD;
&#xD;
          -  Unable to lay still on the back for at least 10 min&#xD;
&#xD;
          -  Abdominal metal implants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Toshia R Myers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toshia Myers</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010 Jan;11(1):11-8. doi: 10.1111/j.1467-789X.2009.00623.x. Epub 2009 Jul 28. Review.</citation>
    <PMID>19656312</PMID>
  </reference>
  <reference>
    <citation>Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, Kirkland JL. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 2013 May 7;17(5):644-656. doi: 10.1016/j.cmet.2013.03.008. Epub 2013 Apr 11. Review.</citation>
    <PMID>23583168</PMID>
  </reference>
  <reference>
    <citation>Unamuno X, Gómez-Ambrosi J, Rodríguez A, Becerril S, Frühbeck G, Catalán V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018 Sep;48(9):e12997. doi: 10.1111/eci.12997. Epub 2018 Aug 3. Review.</citation>
    <PMID>29995306</PMID>
  </reference>
  <reference>
    <citation>Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012 Jan;85(1009):1-10. doi: 10.1259/bjr/38447238. Epub 2011 Sep 21. Review.</citation>
    <PMID>21937614</PMID>
  </reference>
  <reference>
    <citation>de Mutsert R, Gast K, Widya R, de Koning E, Jazet I, Lamb H, le Cessie S, de Roos A, Smit J, Rosendaal F, den Heijer M. Associations of Abdominal Subcutaneous and Visceral Fat with Insulin Resistance and Secretion Differ Between Men and Women: The Netherlands Epidemiology of Obesity Study. Metab Syndr Relat Disord. 2018 Feb;16(1):54-63. doi: 10.1089/met.2017.0128. Epub 2018 Jan 17.</citation>
    <PMID>29338526</PMID>
  </reference>
  <reference>
    <citation>Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients. 2013 Jun 5;5(6):2019-27. doi: 10.3390/nu5062019. Review.</citation>
    <PMID>23739143</PMID>
  </reference>
  <reference>
    <citation>Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The Association of Adiponectin and Visceral Fat with Insulin Resistance and β-Cell Dysfunction. J Korean Med Sci. 2018 Dec 26;34(1):e7. doi: 10.3346/jkms.2019.34.e7. eCollection 2019 Jan 7.</citation>
    <PMID>30618514</PMID>
  </reference>
  <reference>
    <citation>Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015 Jan-Feb;19(1):160-4. doi: 10.4103/2230-8210.146874.</citation>
    <PMID>25593845</PMID>
  </reference>
  <reference>
    <citation>Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One. 2012;7(12):e52036. doi: 10.1371/journal.pone.0052036. Epub 2012 Dec 28.</citation>
    <PMID>23300589</PMID>
  </reference>
  <reference>
    <citation>Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018 Aug 31;17(1):122. doi: 10.1186/s12933-018-0762-4. Review.</citation>
    <PMID>30170598</PMID>
  </reference>
  <reference>
    <citation>King LK, March L, Anandacoomarasamy A. Obesity &amp; osteoarthritis. Indian J Med Res. 2013;138:185-93. Review.</citation>
    <PMID>24056594</PMID>
  </reference>
  <reference>
    <citation>Utzschneider KM, Van de Lagemaat A, Faulenbach MV, Goedecke JH, Carr DB, Boyko EJ, Fujimoto WY, Kahn SE. Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes. Obesity (Silver Spring). 2010 Sep;18(9):1781-7. doi: 10.1038/oby.2010.77. Epub 2010 Apr 8.</citation>
    <PMID>20379148</PMID>
  </reference>
  <reference>
    <citation>Jee SH, Kim HJ, Lee J. Obesity, insulin resistance and cancer risk. Yonsei Med J. 2005 Aug 31;46(4):449-55. Review.</citation>
    <PMID>16127767</PMID>
  </reference>
  <reference>
    <citation>Merlotti C, Ceriani V, Morabito A, Pontiroli AE. Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis. Int J Obes (Lond). 2017 May;41(5):672-682. doi: 10.1038/ijo.2017.31. Epub 2017 Feb 2. Review.</citation>
    <PMID>28148928</PMID>
  </reference>
  <reference>
    <citation>Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond). 2008 Apr;32(4):619-28. doi: 10.1038/sj.ijo.0803761. Epub 2008 Jan 8. Review.</citation>
    <PMID>18180786</PMID>
  </reference>
  <reference>
    <citation>Gomez-Arbelaez D, Bellido D, Castro AI, Ordoñez-Mayan L, Carreira J, Galban C, Martinez-Olmos MA, Crujeiras AB, Sajoux I, Casanueva FF. Body Composition Changes After Very-Low-Calorie Ketogenic Diet in Obesity Evaluated by 3 Standardized Methods. J Clin Endocrinol Metab. 2017 Feb 1;102(2):488-498. doi: 10.1210/jc.2016-2385.</citation>
    <PMID>27754807</PMID>
  </reference>
  <reference>
    <citation>Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab (Lond). 2004 Nov 5;1(1):12.</citation>
    <PMID>15530168</PMID>
  </reference>
  <reference>
    <citation>Romano L, Marchetti M, Gualtieri P, Di Renzo L, Belcastro M, De Santis GL, Perrone MA, De Lorenzo A. Effects of a Personalized VLCKD on Body Composition and Resting Energy Expenditure in the Reversal of Diabetes to Prevent Complications. Nutrients. 2019 Jul 4;11(7). pii: E1526. doi: 10.3390/nu11071526.</citation>
    <PMID>31277506</PMID>
  </reference>
  <reference>
    <citation>Liu FX, Flatt SW, Nichols JF, Pakiz B, Barkai HS, Wing DR, Heath DD, Rock CL. Factors Associated with Visceral Fat Loss in Response to a Multifaceted Weight Loss Intervention. J Obes Weight Loss Ther. 2017;7(4). pii: 346. doi: 10.4172/2165-7904.1000346. Epub 2017 Aug 14.</citation>
    <PMID>29629240</PMID>
  </reference>
  <reference>
    <citation>Johnstone AM. Fasting - the ultimate diet? Obes Rev. 2007 May;8(3):211-22. Review.</citation>
    <PMID>17444963</PMID>
  </reference>
  <reference>
    <citation>Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. Bone. 2017 Nov;104:101-105. doi: 10.1016/j.bone.2017.06.010. Epub 2017 Jun 16.</citation>
    <PMID>28625918</PMID>
  </reference>
  <reference>
    <citation>Finnell JS, Saul BC, Goldhamer AC, Myers TR. Is fasting safe? A chart review of adverse events during medically supervised, water-only fasting. BMC Complement Altern Med. 2018 Feb 20;18(1):67. doi: 10.1186/s12906-018-2136-6.</citation>
    <PMID>29458369</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TrueNorth Health Foundation</investigator_affiliation>
    <investigator_full_name>Toshia Myers</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>water-only fasting</keyword>
  <keyword>HOMA-IR</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>visceral adipose tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

